Evaluatsijata na rizik faktorite vkluchuvashe megju dru-goto: vozrasta na majkata pri kontseptsijata, nivoto na obrazovaniena roditelite, AEL so dozata i ritamot na doziranje, tipot i etio-logijata na epilepsijata kaj majkata, pochetok i traenje na epilep-sijata, tipot na napadi i nivnata frekfentsija za vreme na bre-menosta, postoenje na drugi khronichni i interkurentni bolesti kajmajkata, familijarnata istorija za kongenitalni majorni malfor-matsii, poznati khereditarni bolesti i epilepsija megju prvoste-penite rodnini na fetusot.REzUlTATIOtkako gi iskluchivme bremenostite koi zavrshija so spontani iliindutsirani abortusi, nie gi analiziravme iskhodite na bremenostavo odnos na pojata na majorni kongenitalni malformatsii kaj 84bremenosti od R. Makedonija.Majorni kongenitalni malformatsii bea najdeni kaj 3 bremenosti,od koi kaj ednata se raboteshe za prva bremenost, a kaj drugite dvese raboteshe za vtora bremensot, so zdravi detsa kako iskhod odprvite bremenosti vo ovie dva sluchai. Prvata bremenost kojazavrshi so mashko novorodenche so majorna kongenitalna malforma-tsija tetralogia Fallot se sluchi kaj majka so idiopatska generalizira-317fIfth congress of pharmacy of macedonIa WIth InternatIonal partIcIpatIonMacedonian Pharmaceutical Bulletin 57 (suppl), 2011CLINICAL PHARMACY oral presentationsna epilepsija ( IGE) koja zemashe AEL i toa fenobarbiton tabletiso ednokratno dnevno doziranje od 100 mg. Majkata imashe kontrolana napadite, za vreme na bremenosta nemashe epileptishni napadiod tipot na generalizirani tonichno-klonichni ili drugi napadi,no koristeshe dopolnitelna terapija na tableti folan od 5 mgsamo vo tekot na eden mesets od prvoto tromesechie na bremenosta.Taa za vreme na bremenosta koristela alkokhol i pushela od nekolkudo 10 tsigari dnevno. Nejzinata vtora bremenot beshe zdravo zhenskonovorodenche. Za vreme na vtorata bremenost majkata koristeshevalproat monoterapija kako antiepileptichna terapija, dodatnaterapija na folan od 5 mg za vreme na tselata bremenost i go preki-na potpolno koristenjeto na alkokhol i tsigari za vreme na bremeno-sta. Kaj vtoriot sluchaj, iskhodot od vtorata bremenost na edna odmajkite beshe zhensko novorodeno so kongenitalna malformatsijaod vidot na polidaktilija, so pojava na shesti prst na dvete shakikoj poagjashe od paletsot. Pvrata bremenost na ovaa majka zavrshi soragjanje na zdravo mashko dete. Taa imashe kriptogena forma natemporalna epilepsija, bez kontrola na napadite. Za vreme na bre-menosta taa manifestiranje kompleksni partsijalni napadi so che-stota od nekolku napadi mesechno. Taa koristeshe politerapija odAEL. Iskhodot na vtorata bremenost kaj tretiot sluchaj na bremenostso majorni kongernitalni malformatsii rezultirashe so lumbalnameningomielotsela. Majkata imashe IGE so kontrola na napadite soAET valproat vo doziranje od po 300 mg dva pati dnevno i koriste-nje na dopolnitelna terapija na folan od 0,4 mg dnevno, namesto 5mg folan dnevno kako shto koristela za vreme na prvata bremenostso povolen iskhod.zAKlUChOKRizikot od majorni kongenitalni malformatsii kaj bremeni soepilepsija koi koristat AEL ne e samo pod vlijanie na vidot na AEL,no zavisi i od drugi faktori koi treba da se zemat vo obzir primenedzhiranjeto na epilepsijata kaj zheni vo generativniot period.optImIzatIon of elIsa methodfor determInatIon of serumantI-gm1 antIbodIesAna Poceva Panovska1, Katerina Brezovska1,Aleksandra Grozdanova1, Slobodan Apostolski 2,Ljubica Suturkova11Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Mace-donia2Outpatient Neurological Clinic, Belgrade, SerbiaIntroductIonAnti-ganglioside antibodies (anti-GAb) assays have been widely usedas a research tool in studying autoimmune peripheral neuropathies[1]. Quantification of circulating antibodies has been suggested as use-ful for diagnosis, since there is well-known correlation between spe-cific neuropathies and anti-GAb [1-4]. Titer of these antibodies is usedas a predictive marker in Guillain-Barre syndrome (GBS), since high con-centration predicts a severe course and poor prognosis of the disease.In some neuropathies such as multifocal motor neuropathy (MMN),anti-GAb are response analyte for monitoring the therapy. Patient witha therapeutic reduction in anti-GAb concentration has been associ-ated with clinical improvement [1-5]. These antibodies are routinelymeasured by the enzyme linked immunosorbent assay (ELISA) that de-tects serum antibodies binding to ganglioside coated well. Usually con-firmation of a positive serum is done using thin layer chromatographywith subsequent immunodetection [4]. There are several other alter-natives such as agglutination immunoassay that detects antibodybinding to ganglioside-coated microspheres [6] and dot or line im-munoassay that may be a good alternative for the multiparametricdetermination of anti-GAb [7].There are reported variation of the results obtained by ELISA methodfor different patient groups and controls. These variations couldlargely be explained by differences in established in-house protocolsbased on the previously published assays methods. Many factors thatinfluence the assay have been identified. They include gangliosidesource, types of ELISA plates used, coating methods, secondaryreagents and other differences in protocol details [8].In order to obtain reliable protocol for determination of anti-GM1 anti-ganglioside antibodies we optimized the existing in-house protocoland established the cut off values for IgG and IgM antibodies using re-ceiver-operating characteristic (ROC) analysis.experImentalOn a standard 96-well plate each well in the rows A,C,E and G wascoated with 200 ng GM1 in 100 ul absolute ethanol. Wells in the re-maining rows were coated with the solvent and it was left to evaporateat the room temperature (RT). Blocking of nonspecific binding siteswas done with 1% BSA in PBS for 2 hours at 4 oC. Wells were washedwith 0.1% BSA/PBS. The test sera (1:200) were added in duplicate, se-rially diluted to 1:6400 and incubated over night (ON) at 4 oC. Plateswere washed (0.1% Tween 20 in 0.1% BSA/PBS) and peroxidase conju-gated goat anti-human IgG (1:1000) was added to the wells and incu-bated for 2 hours at 4 oC. After washing color was developed by adding100 ul of substrate solution (0,25 mg/ml OPD in citrate buffer) and 30%H2O2 and after 20 min reaction was stopped with 3M H2SO4 and ab-sorbance was read at 490 nm. As a control for GM1 well coating bi-otinylated cholera toxin (CT) was used.To determine anti-GM1 reactivity, the mean difference of optical den-sities (d-OD) of two GM1-coated wells and two uncoated wells wasused. To evaluate cut-off values for positive IgM and IgG anti-GM1 re-activity, a ROC curve was made using MedCalc(r) v11.6 software. TheROC-curves were based on the available d-OD results of 24 MMN pa-tients for IgM and 24 GBS patients for IgG since these patient sub-groups show relative highest and most frequent reactivity for theseisotypes in the literature and in this study [9]. To determine the ROC-curves, the d-OD results of 24 blood donors were used as a controlgroup (HC) for both isotypes. The reciprocal of the highest dilutionthat resulted in an OD higher than the cut-off value was taken to bethe titer.results and dIscussIonAssay optimizationFor the optimization of ELISA procedure different factors were ana-lyzed. The major problem of the existing protocol was high background(absorbance of the sera added to wells without ganglioside) that in-terfered with the correct estimation of the specificity and sensitivityof the antibodies.In the present study we used flat bottom-high binding microtiterplates. Absolute ethanol was selected as a suitable solvent for coatingsince it is the most exploit in the literature and it gives more repro-318PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011KLINIChKA FARMATsIJA oralni prezentatsiiducible results.The optimal antigen coating concentration and dilution of secondaryantibody was determined using checkboard titration and set at 0.2ug/100ul per well for GM1 and dilution of 1:1000 for secondary anti-body.Various concentrations of PBS-BSA blocking solution were examinedand the optimal was set to 10g/L.In the washing steps after varying the concentration of the detergentTween 20 it was established that 0.1% of the detergent in 0.1%BSA/PBS optimally reduces the background absorption.Determination of cut-off valuesThe ROC analysis was performed to determine the optimal cut-off val-ues for positive IgG and IgM anti-GM1 reactivity and to discriminate be-tween patients and controls. As a negative state variable we usedresults of the d-OD from HC and as positive state variable, results ofd-OD for IgM and IgG obtained from patients with MMN and GBS, re-spectively (Fig. 1). ROC analysis indicated a corresponding specificityof 100% for IgM and a specificity of 100% for IgG with sensitivities of46% and 21%, respectively. The area under the ROC curve for IgM was0.78 and for IgG 0.67.Fig 1. ROC curves for anti-GM1 reactivityThe optimal cut-off value based on the ROC analysis was set to 0.3 forIgM and 0.2 for IgG. Lower cut-off values will increase the sensitivitybut also will result in an unwanted higher false positive fraction. Werecommend a lower false positive fraction in favor of a higher sensi-tivity.conclusIonWe optimized ELISA method for determination of serum anti-GM1 an-tibodies that can be used as a diagnostic tool for immune-mediatedperipheral neuropathies.references[1] Adams D, Kuntzer T, Burger D, Choffon M, Magistris MR, Regli F, Steck AJ (1991) JNeuroimmunol 32 223-230[2] Sadiq SA, Thomas FP, Kilidireas K, Protopsaltis S, Hays AP, Lee KW, et al. Neurol-ogy 1990;40:1067-72. [3] Berg LH, Marrink AEJ, Jong HJ, Imhoff GW, Latov N, Sadiq SA. J Nerurol NeurosurgPsych 1992;55:8-11. [4] Willison HJ, Yuki N. Brain 2002;125(Pt 12):2591- 625. [5] Feldman EL, Bromberg MB, Alberes JW, Pestronk A. Ann Neurol 1991;30:397-401. [6] Alaedini A, Latov N. J Clin Lab Anal 2001;15:96-9[7] A New Line Immunoassay for the Multiparametric Detection of AntigangliosideAutoantibodies in Patients with Autoimmune Peripheral Neuropathies[8] Ravindranath MH, Ravindranath RM, Morton DL, Graves MC 1994 Factor affectingthe fine specificity and sensitivity of serum antiganglioside antibofies in ELISA, 169:257-72[9] Kuijf M, van Doorn P, Tio-Gillen A, Geleijns K, Ang W Hooijkaas H, Hop W. JacobsB (2005) J Neurol Sci, 239; 37 - 44[10] Bech E, Jakobsen J, Orntoft T, ELISA-Type Titertray Assay of IgM anti-GM1 au-toantibodies (1994) Clin Chem 40/7, 1331-4OPTIMIzATsIJA NA elIsa METODzA OPREDElUVAnjE NA SERUMSKIANTI-gm1 ANTITElAAna Potseva Panovska1, Katerina Brezovska1,Aleksandra Grozdanova1, Slobodan Apostolski 2,Ljubitsa Shuturkova11Farmatsevtski Fakultet, Univerzitet Sv Kiril i Metodij, Skopje,Makedonija2Spetsijalistichka ordinatsija za nevrologija 'Apostolski', Belgrad,SrbijaVOVEDTestovite za opredeluvanje na anti-gangliozidni antitela (anti-GAb) imaat shiroka primena vo istrazhuvanjata na avtoimunite peri-ferni nevropatii [1]. Kvanitifkatsijata na anti-GAb e osobenokorisna kaj nevropatii za koi e dokazhno postoenjeto na korelatsi-jata so anti-GAb [1-4]. Titarot na anti-GAb mozhe da se koristi kakoprediktiven marker. Kaj Guillain-Barre sindromot (GBS), visokiottitar na anti-GM1 antitelata, korelira so tezhok tek i losha pro-gnoza na bolesta. Kaj nekoi nevropatii kako multifokalnata mo-torna nevropatija (MMN), anti-GAb se analit preku koj mozhe da sesledi iskhodot od terapijata. Patsientite kaj koi vo tekot na terapi-jata doagja do reduktsija na anti-GAb generalno imaat podobra kli-nichka slika [1-4].Opredeluvanjeto na anti-GAb rutinski se izveduva so ELISA(Enzyme Linked Immunosorbent Assay). Najchesto za potvrda napozitivniot serum mozhe da se koristi tenkoslojna khromatografijaso imunodetektsija [4]. Postojat i drugi metodi za opredeluvanje naanti-GAb kako aglutinatsiskiot imunotest [6] i 'dot' ili 'line' imu-notestot [7].Razliki vo rezultatite za anti-GAb dobieni so ELISA kaj razlichnigrupi na patsienti i kontroli, glavno se dolzhat na razlikite vovospostavenite 'in-house' laboratoriski protokoli. Nekoi odfaktorite koi vlijaat na rezultatite od testot se razlichnoto po-teklo na gangliozidite, razlichni tipovi na ELISA plochi, metodi naoblozhuvanje na plochite, sekundarni reagensi i drugi razliki vodetalite na izveduvanje na postapkata [8].So tsel da se dobie siguren protokol za opredeluvanje na anti-GAboptimiziran e postoechkiot laboratoriski protokol i opredelenise granichnite vrednostite na otfrlanje (cut-off) na testot za IgG iIgM antitelata koristejki ROC (Receiver-Operating Characteristic)analiza.EKSPERIMENTAlEN DElELISA postapkaNa plocha so 96 bunarchinja redovite A,C,E i G bea oblozheni so200 ng GM1/100 ul absoluten etanol.